Kongress-Beiträge 2025

Gepoolte Analysen

Marco Maria Germani, Beatrice Borelli, Tadayoshi Hashimoto, Yoshiaki Nakamura, Andrea Bottelli, Francesca Battaglin, Sara Lonardi, Lisa Salvatore, Arndt Stahler, Kohei Shitara, Alan Venook, Eiji Oki, Kei Muro, Clara Ugolini, Junpei Soeda, Filippo Pietrantonio, Heinz-Josef Lenz, Dominik Modest, Takayuki Yoshino, Chiara Cremolini. The prognostic and predictive role of HER2 amplification/overexpression and HER2 mutations in metastatic colorectal cancer treated with first-line chemotherapy plus bevacizumab/anti-EGFRs: An individual patient data pooled analysis of eight randomized trials. J Clin Oncol 43 (no. 16_suppl): 3537 (2025). DOI: 10.1200/JCO.2025.43.16_suppl.3537 (Abstract #3537 Poster #206 ASCO Annual Meeting 2025 – Panama)

Marco Maria Germani, Roberto Moretto, Arndt Stahler, Tadayoshi Hashimoto, Federica Morano, Alan Venook, Sebastian Stintzing, Yoshiaki Nakamura, Giacomo Di Paolo, Francesca Battaglin, Kathrin Heinrich, Kei Muro, Francesca Bergamo, Dominik Modest, Junpei Soeda, Carlotta Antoniotti, Heinz-Josef Lenz, Takayuki Yoshino, Volker Heinemann, Chiara Cremolini. Assessing the predictive role of tumor sidedness in RAS and BRAF wild-type metastatic colorectal cancer (mCRC) treated with first-line doublets + anti-EGFRs/bevacizumab (bev) or triplet + bev: An individual patient data pooled analysis of 10 randomized clinical trials. J Clin Oncol 43 (no. 16_suppl): 3538 (2025). DOI: 10.1200/JCO.2025.43.16_suppl.3538 (Abstract #3538 Poster #207 ASCO Annual Meeting 2025 - Panama)

Lena Dreikhausen, Ling Wang, Nadja Meindl-Beinker, Amelie Franken, Isabella Wiest, Ralph Keller, Viktor Grünwald, Leo Andrae, Rogier Schepers, Thomas Van Brussel, Xavier Sagaert, Diether Lambrechts, Matthias Ebert. Serum and tumor immune cell distribution as predictor of response to immune checkpoint blockade in solid tumors. J Clin Oncol 43 (no. 16_suppl): e16029 (2025).  DOI: 10.1200/JCO.2025.43.16_suppl.e16029 (Abstract #e16029, Publication Only ASCO Annual Meeting 2025)

Lena Weiss, Sebastian Stintzing, Dominik Modest, Ludwig von Weikersthal, Arndt Stahler, Anke Reinacher-Schick, Thomas Decker, Victoria Probst, Kathrin Heinrich, Ingo Schwaner, Florian Kaiser, Rudolf Pihusch, Martin Fuchs, Swantje Held, Annabel Alig, Birgit Gruenberger, Gerald Prager, David Tougeron, Julien Taieb, Volker Heinemann. Impact of anti-EGFR and anti-VEGF antibodies on survival in BRAFV600E mutated metastatic colorectal cancer: A pooled analysis of eight clinical trials performed in the first-line treatment of mCRC (German AIO Study Group). J Clin Oncol 43 (no. 16_suppl): 3543 (2025). DOI: 10.1200/JCO.2025.43.16_suppl.3543 (Abstract #3543 Poster #212 ASCO Annual Meeting 2025 -  Panama und Volfi)

NeoTRACE

Friederike Althoff, Fabian Acker, Sebastian Koschade, Sophie Heinzen, Lukas Aguinarte, Maximilian Rost, Hanna Schulte, Gernot Rohde, Melanie Demes, Waldemar Schreiner, Katrin Krause, Viktor Grünwald, Hubert Serve, Thomas Oellerich, Martin Sebastian. Neotrace: A multicenter phase II study of neoadjuvant sacituzumab govitecan plus zimberelimab followed by adjuvant zimberelimab with or without sacituzumab govitecan in patients with resectable non-small cell lung cancer. J Clin Oncol 43 (no. 16_suppl): TPS8120 (2025). DOI: 10.1200/JCO.2025.43.16_suppl.TPS8120 (Abstract #TPS8120 Poster #237b ASCO Annual Meeting 2025)

ATOMIC

Frank Sinicrope, Fang-Shu Ou, Dirk Arnold, Walter Peters, Robert Behrens, Christopher Lieu, Khalid Matin, Deirdre Cohen, Samara Potter, Wendy Frankel, Ardaman Shergill, Dennis Hsu, Anke Reinacher-Schick, Tyler Zemla, Clare Gatten, Eileen O'Reilly, Jeffrey Meyerhardt. Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC). J Clin Oncol 43, 2025 (suppl 17; abstr LBA1). J Clin Oncol 43 (no. 17_suppl): LBA1 (2025). Doi: 10.1200/JCO.2025.43.17_suppl.LBA1 (Abstract #LBA1, Plenary Session ASCO Annual Meeting 2025)

GOBLET

Dominik Paul Modest, Eray Goekkurt, Thomas Charles Heineman, Uwe Marc Martens, Anke C. Reinacher-Schick, Jack Chater, Thomas Seufferlein, Matt Coffey, Ruimei Li, Richard Trauger, Dirk Arnold. GOBLET platform study: Preliminary Safety and Tumor Response Results for the Relapsed Anal Carcinoma Cohort in Patients Treated with Pelareorep and Atezolizumab. J Clin Oncol 43 (no. 4_suppl): 6. DOI:10.1200/JCO.2025.43.4_suppl.6 (Poster ASCO GI 2025)

Thomas Seufferlein, Dirk Arnold, Nina Burkhart, Anke C. Reinacher-Schick, Guy Ungerechts, Uwe Marc Martens, Jack Chater, Eray Goekkurt, Jenns Siveke, Matt Coffey, Ruimei Li, Katherine Parsons, Thomas C. Heineman. GOBLET study: Results of the Safety Run-in for First-line Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Patients Treated with Pelareorep + Modified FOLFIRINOX +/- Atezolizumab. J Clin Oncol 43 (no. 4_suppl): 730 (2025). DOI:10.1200/JCO.2025.43.4_suppl.730 (Poster ASCO GI 2025)

PREDICT

Anton Lahusen, Manfred Lutz, Meinolf Karthaus, Martina Kirchner, Klaus Kluck, Sarah Wisser, Phyllis Fung-Yi Cheung, Nikolaus Ansorge, Christof Burkart, Thomas Decker, Ludwig Fischer von Weikersthal, Thomas Geer, Anke Gerhardt, Jan Budczies, Jens Siveke, Andrea Tannapfel, Thomas Seufferlein, Albrecht Stenzinger, Tim Eiseler, Thomas Ettrich. A PBMC and machine learning based biomarker signature to predict second line chemotherapy success in advanced PDAC: Translational data of the PREDICT trial—A prospective, multicenter, trial of the AIO Pancreatic Cancer Group (AIO-PAK-0216). J Clin Oncol 43 (no. 16_suppl): 4187 (2025). DOI: 10.1200/JCO.2025.43.16_suppl.4187 (Abstract #4187 Poster #477 ASCO Annual Meeting 2025)

NEONAX

Thomas Ettrich, Waldemar Uhl, Marko Kornmann, Hana Algül, Helmut Friess, Alexander Koenig, Thomas Gress, Eike Gallmeier, Manfred Lutz, Kai Wille, Carl Schimanski, Volker Kunzmann, Dirk Waldschmidt, Severin Daum, Swantje Held, Lukas Perkhofer, Jasmin Schuhbaur, Margaret Tempero, Anke Reinacher-Schick, Thomas Seufferlein. Five-year outcomes of perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (the NEONAX trial): A randomized phase II trial of the AIO pancreatic cancer group. J Clin Oncol 43 (no. 16_suppl): 4193 (2025). Doi: 10.1200/JCO.2025.43.16_suppl.4193 (Abstract #4193 Poster #483 ASCO Annual Meeting 2025)

Thomas Seufferlein, Anton Lahusen, Martina Kirchner, Mohamed Ali Jarboui, Klaus Kluck, Sarah Wisser, Waldemar Uhl, Marko Kornmann, Hana Algül, Helmut Friess, Jasmin Schuhbaur, Alexander Kleger, Lukas Perkhofer, Jan Budczies, Margaret A. Tempero, Anke C. Reinacher-Schick, Albrecht Stenzinger, Andrea Tannapfel, Tim Eiseler, and Thomas Jens Ettrich. Machine learning–based liquid biomarker analysis from the NEONAX trial for response prediction to perioperative (PO) and adjuvant (A) gemcitabine/nab-paclitaxel in resectable PDAC (rPDAC). J Clin Oncol 43 (no.4_suppl.): 755 (2025). doi.org/10.1200/JCO.2025.43.4_suppl.75 (Abstract #755 Poster ASCO GI 2025)

PanaMa

Alexej Ballhausen, Nooshin Omranian, Orr Shomroni, Arndt Stahler, Meinolf Karthaus, Stefan Fruehauf, Ullrich Graeven, Greta Sommerhäuser, Annabel Alig, Eray Goekkurt, Johanna Meyer-Knees, Annika Kurreck, Swantje Held, Volker Heinemann, Stefan Kasper, Sebastian Stintzing, Tanja Trarbach, Markus Ralser, Michael Mülleder, Dominik Modest. Prognostic and predictive impact of the baseline systemic proteome in patients with RAS wild-type metastatic colorectal cancer: Analysis from the randomized phase II PanaMa (AIO KRK0212) trial. J Clin Oncol 43 (no. 16_suppl): 3546 (2025). Doi: 10.1200/JCO.2025.43.16_suppl.3546 (Abstract #3546 Poster #215 ASCO Annual Meeting 2025)

PREPARE

Viktor Grünwald, Lutz Jacobasch, Maike de Wit, Severine Banek, Guenter Niegisch, Mark-Oliver Zahn, Andreas Neisius, Phillip Marks, Mirko Müller, Ludwig von Weikersthal, Andreas Huebner, Marinela Augustin, Eyck von der Heyde, Christian Thomas, Nils Gilbert, Alexander Fehr, Heribert Stauder, Ursula Vehling-Kaiser, Ralf Eckert, and Philipp Ivanyi IAG-N. A phase III study testing the role of proactive coaching on patient reported outcome in advanced or metastatic renal cell carcinoma treated with sunitinib or a combination of axitinib + pembrolizumab or avelumab in first line therapy (PREPARE; AIO-NZK-0115/ass). J Clin Oncol 43 (no. 5_suppl): 523 (2025). https://doi.org/10.1200/JCO.2025.43.5_suppl.523 (Poster #523 ASCO GU 2025)